Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2022 Jan 17;31(5):566–576. doi: 10.1002/pds.5406

Figure 2. Development timeline for SGLT-2i and study time blocks.

Figure 2.

2013/03: FDA approval for canagliflozin (Invokana®) to treat T2D.

2014/01: FDA approval for dapagliflozin (Farxiga®) to treat T2D.

2014/08: FDA approval for empagliflozin (Jardiance®) to treat T2D.

2015/11: Publication of the EMPA-REG OUTCOME trial results for empagliflozin.

2016/12: FDA label change for empagliflozin to indicate cardiovascular benefits.

Advance of SGLT-2i to second-line agent by the American Diabetes Association (ADA).

2017/08: Publication of the CANVAS trial results for canagliflozin.

2018/01: ADA endorsement of SGLT-2i as a preferred second-line agent for patients with CVD.

2018/10: FDA label change for canagliflozin to indicate cardiovascular benefits.

2019/01: Publication of the DECLARE-TIMI 58 trial results for dapagliflozin.

2019/10: FDA label change for dapagliflozin to indicate cardiovascular benefits.